Dana Pizzuti, M.D., serves as the Chief Development Officer at Crinetics Pharmaceuticals Inc., a biopharmaceutical company focused on developing novel therapeutics for endocrine diseases and endocrine-related tumors. Dr. Pizzuti brings a wealth of experience in drug development, clinical research, and medical affairs to her role. She has been instrumental in advancing Crinetics' pipeline, overseeing the strategic direction and execution of clinical development programs aimed at bringing innovative treatments to patients with unmet medical needs. Prior to joining Crinetics, Dr. Pizzuti held significant positions in the pharmaceutical industry, including roles at Amgen and Shire. At Amgen, she was the Therapeutic Area Head for Cardiovascular and Metabolic Disorders, where she led the development of several key products. Her tenure at Shire saw her as the Vice President of Clinical Development, where she successfully guided multiple programs through various stages of clinical trials. Dr. Pizzuti's academic credentials include a medical degree from the University of Pennsylvania and residency training in internal medicine at the Hospital of the University of Pennsylvania. Her expertise in endocrinology and metabolism, combined with her strategic leadership, has been pivotal in driving Crinetics' mission forward. In her current role at Crinetics, Dr. Pizzuti is responsible for steering the company's clinical development strategy, ensuring that Crinetics' investigational therapies progress efficiently from early-stage research through to late-stage clinical trials and eventual market approval. Her leadership has been crucial in the advancement of Crinetics' lead candidate, paltusotine, a potential treatment for acromegaly and carcinoid syndrome. Under her guidance, the company has achieved significant milestones, including successful Phase 2 trial results and the initiation of Phase 3 studies. Dr. Pizzuti's dedication to improving patient outcomes and her ability to navigate the complexities of drug development make her an invaluable asset to Crinetics Pharmaceuticals.